Longitudinal Volumetric and 2D Assessment of Cerebellar Atrophy in a Large Cohort of Children with Phosphomannomutase Deficiency (PMM2-CDG)
Overview
Authors
Affiliations
Objective: We aim to delineate the progression of cerebellar atrophy (the primary neuroimaging finding) in children with phosphomannomutase-deficiency (PMM2-CDG) by analyzing longitudinal MRI studies and performing cerebellar volumetric analysis and a 2D cerebellar measurement.
Methods: Statistical analysis was used to compare MRI measurements [midsagittal vermis relative diameter (MVRD) and volume] of children with PMM2-CDG and sex- and age-matched controls, and to determine the rate of progression of cerebellar atrophy at different ages.
Results: Fifty MRI studies of 33 PMM2-CDG patients were used for 2D evaluation, and 19 MRI studies were available for volumetric analysis. Results from a linear regression model showed that patients have a significantly lower MVRD and cerebellar volume compared to controls (p < 0.001 and p < 0.001 respectively). There was a significant negative correlation between age and MVRD for patients (p = 0.014). The rate of cerebellar atrophy measured by the loss of MVRD and cerebellar volume per year was higher at early ages (r = -0.578, p = 0.012 and r = -0.323, p = 0.48 respectively), particularly in patients under 11 years (p = 0.004). There was a significant positive correlation between MVRD and cerebellar volume in PMM2-CDG patients (r = 0.669, p = 0.001).
Conclusions: Our study quantifies a progression of cerebellar atrophy in PMM2-CDG patients, particularly during the first decade of life, and suggests a simple and reliable measure, the MVRD, to monitor cerebellar atrophy. Quantitative measurement of MVRD and cerebellar volume are essential for correlation with phenotype and outcome, natural follow-up, and monitoring in view of potential therapies in children with PMM2-CDG.
Glycosylation and behavioral symptoms in neurological disorders.
Pradeep P, Kang H, Lee B Transl Psychiatry. 2023; 13(1):154.
PMID: 37156804 PMC: 10167254. DOI: 10.1038/s41398-023-02446-x.
[Advances in the diagnosis and treatment of phosphomannomutase 2 deficiency].
Zhou S Zhongguo Dang Dai Er Ke Za Zhi. 2023; 25(2):223-228.
PMID: 36854702 PMC: 9979379. DOI: 10.7499/j.issn.1008-8830.2209049.
Martinez-Rubio D, Rodriguez-Prieto A, Sancho P, Navarro-Gonzalez C, Gorria-Redondo N, Miquel-Leal J Hum Mol Genet. 2022; 31(22):3897-3913.
PMID: 35766882 PMC: 9652108. DOI: 10.1093/hmg/ddac146.
Stroke-Like Episodes in PMM2-CDG: When the Lack of Other Evidence Is the Only Evidence.
Serrano M Front Pediatr. 2021; 9:717864.
PMID: 34708008 PMC: 8542667. DOI: 10.3389/fped.2021.717864.
Martinez-Monseny A, Edo A, Casas-Alba D, Izquierdo-Serra M, Bolasell M, Conejo D Int J Mol Sci. 2021; 22(10).
PMID: 34068417 PMC: 8153625. DOI: 10.3390/ijms22105180.